Abstract
The right to health under the International Covenant on Economic, Social, and Cultural Rights, to which Canada is a signatory, entitles women to available, accessible, and acceptable abortion care. Abortion care in Canada currently fails this standard. Medication abortion (the use of drugs to terminate a pregnancy) could improve abortion care in Canada, but its potential remains unrealized.
This is in part attributable to the unavailability of mifepristone, the safest and most effective pharmaceutical for medication abortion. Given that it could improve abortion care, we investigated why mifepristone remains unapproved in Canada, whether its unavailability is attributable to government inaction, and whether Canada is therefore failing to fulfill its obligations under the right to health.
| Original language | Canadian English |
|---|---|
| Journal | Articles, Book Chapters, & Popular Press |
| Publication status | Published - Jan. 1 2008 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being -
SDG 16 Peace, Justice and Strong Institutions
Keywords
- Medication Abortion
- Abortion Care
- Public Health
- Right To Health
- Mifepristone
- International Covenant on Economic
- Social
- and Cultural Rights
- International Obligations
- Canada
Disciplines
- Health Law and Policy
- Human Rights Law
- International Law
- Law
- Medical Jurisprudence
Fingerprint
Dive into the research topics of 'Medication Abortion in Canada: A Right-to-Health Perspective'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver